Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Operating Income to Total Debt for the Trailing 12 Months (TTM) ending March 31, 2024

Anebulo Pharmaceuticals Inc Operating Income to Total Debt is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The operating income to total debt ratio measures the ability of a company's operating income to cover its total debt obligations. It is calculated by dividing the operating income by the total debt. This ratio provides insights into the company's ability to generate income from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating income relative to the level of debt, suggesting potential financial strength and debt servicing capability.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email